PathAI logo

Comparison of the effects of semaglutide on liver histology in patients with non-alcoholic steatohepatitis cirrhosis between machine learning model assessment and pathologist evaluation

AASLD 2022

Study Background

  • Liver biopsies evaluated by hepatopathologists are a key method for assessing treatment response in trials of non-alcoholic steatohepatitis (NASH).1,2 
    • Artificial intelligence has also shown promise in liver biopsy assessment.2
  • Identification and assessment of NASH components can be subject to inter- and intra-observer variability, especially for hepatocyte ballooning.3
  • This post hoc analysis aimed to assess the effect of semaglutide vs placebo on histological components of NASH as assessed by a pathologist and PathAI’s machine learning (ML) models.
    • The analysis used data from a randomized, double-blind, placebo-controlled phase 2 trial investigating once-weekly subcutaneous semaglutide 2.4 mg in patients with NASH and compensated cirrhosis.
  1. NAFLD Research Center, University of California San Diego, La Jolla, CA, USA;
  2. Novo Nordisk A/S, Søborg, Denmark;
  3. PathAI, Inc., Boston, MA, USA;
View Poster


Loomba et al.